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BIS-QUATERNARY AMMONIUM SALTS AND

2
norepinephrine (NE) release, [3H]serotonin (5-HT) release,

METHODS FOR MODULATING NEURONAL
NICOTINIC ACETYLCHOLINE RECEPTORS

glutamate release) from superfused rat brain slices. Nicotinic

[3H]gamma-aminobutyric acid (GABA) release and [3H]
receptors are located in the cell body and terminal areas of
these neurotransmitter systems. NIC facilitates neurotrans
mitter release from nerve terminals.
The structural and functional diversity of central nervous
system nicotinic receptors has stimulated a great deal of inter

CONTINUING APPLICATION DATA

This application claims bene?t of US. Provisional Appli
cation No. 60/8 1 4,640, ?led Jun. 16, 2006, Which is incorpo
rated herein by reference in its entirety.

est in developing novel, subtype-selective agonists and/or
antagonists. Some of these agonists are currently being evalu
ated in clinical trials for cognitive enhancement and neuro

IDENTIFICATION OF FEDERAL FUNDING

protective effects, potentially bene?cial for disease states
such as AlZheimer’s and Parkinson’s disease, as Well for

The present invention Was supported by Grant NIH
Ul9DA0l7548 from the National Institutes of Health, and
therefore the government may have rights in the invention.

treatment of drug abuse, depression, obesity and pain relief.
SUMMARY OF INVENTION

FIELD OF THE INVENTION

The invention relates to bis-quatemary ammonium salts
and their use in modulating nicotinic acetylcholine receptors.

In one embodiment, compounds corresponding to the fol
loWing structure are provided.
20

S-Nicotine (NIC) activates presynaptic and postsynaptic
25

rotransmitters from presynaptic terminals and that modulate
the depolariZation state of the postsynaptic neuronal mem

L1 and L2 are each independently selected from alkyl, sub
30

channel to open and cations to ?ux With a resulting rapid

(millisecond) depolarization of the target cell.
Neuronal nicotinic receptors are composed of tWo types of
subunits, 0t and [3, and assemble as heteromeric receptors With
the general stoichiometry of 2a and 3[3 or as homomeric
receptors With 5a subunits. Nine subtypes of the ot subunit

stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substi
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substi
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalky
nyl, substituted arylalkynyl, heterocyclic, substituted

heterocyclic; SOYl, SOZYI, SOZOYl or SO2NHYl, WhereYl
35

is selected from hydrogen, loWer alkyl, alkenyl, alkynyl or
aryl, and where Y1 is not hydrogen in SOYl and if Y1 is
alkenyl or alkynyl, the site of unsaturation is not conjugated
With a heteroatom; COY2, Where Y2 is selected from hydro

40

cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub
stituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, sub
stituted alkylaryl, arylalkyl, substituted arylalkyl, arylalk
enyl, substituted arylalkenyl, arylalkynyl, substituted

(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are
found in the central nervous system. The mo st common nico

gen, alkyl, substituted alkyl, cycloalkyl, substituted

tinic receptor subtype in the brain is composed of tWo (X4 and

three [32 subunits, i.e., (X462. These subunits display different,

ganic anion.
Q is selected from phenylene, biphenylene, 4CH:CHi,
4CH:CH4CH:CHi, iCECi, 4CECiCECi,
4Oi(CH2)24Oi, and 4Oi(CH2)24Oi(CH2)2i
0*.

brane, respectively. Thus, S-nicotine produces its effect by
binding to a family of ligand-gated ion channels, stimulated
by acetylcholine (ACh) or S-nicotine Which causes the ion

(I)

XIQ and X2© are each independently an organic or inor

BACKGROUND OF THE INVENTION

neuronal nicotinic receptors that evoke the release of neu

XZQG-DRIiHZC-LIQ-LZ-CHZiRZG-DQXI

but overlapping, patterns of expression in the brain. Examples
of heteromeric receptor subtypes include (X462, (X362, (X3 [34,

(X662, (x6[32[33, (x40t5[32, (x60t5[32, (x60t4[32, (x60t4[32[33,
proposed.

arylalkynyl, heterocyclic, or substituted heterocyclic, and
Where if Y2 comprises alkenyl or alkynyl, the site of unsat
uration is not conjugated With the carbonyl group; 0Y3,

For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to

Where Y3 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk

(x4[32[34, 3[32[34, and others. The predominant homomeric
subtype includes (x7, but other combinations have also been

be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid

45

50

sequence at the subunit level and from the multiple combina
tions of assemblies of subunits into functional receptor pro
teins, Which affords a Wide diversity of pharmacological

speci?city.
In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many studies. [3H]NIC

55

appears to label the same sites in the brain as [3H]ACh. It has

been estimated that over 90% of [3H]NIC binding in the brain
is due to association With the heteromeric receptor that is
composed of (X4 and [32 subunits. Also abundant in the central
nervous system are the homomeric receptors labeled by [3 H]

methyllycaconitine (MLA), Which has high af?nity for the (X7
nicotinic receptor subtype. Nicotinic receptor subtypes can
be studied using functional assays, such as NIC-evoked neu

rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H]

60

enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or
substituted heterocyclic, Where if Y3 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated With the
oxygen; NY4Y5, Where Y4 and Y5 are each independently

selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted
heterocyclic, Where if Y4 orY5 comprises alkenyl or alkynyl,
the site of unsaturation is not conjugated With the nitrogen;

SY6, Where Y6 is selected from hydrogen, alkyl, substituted
65

alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla

US 8,178,678 B2
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3
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi

A9 is carbon, nitrogen, sulfur or oxygen, provided that

tuted arylalkynyl, heterocyclic, or substituted heterocyclic,
and Where if Y6 comprises alkenyl or alkynyl, the site of

When A9 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R20 is absent, and When A9 is sulfur or

unsaturation is not conjugated With the sulfur.
R1 and R2 are each independently ?ve or six membered

nitrogen, both R20 and R21 are absent.

oxygen or joins a ring atom With an unsaturated bond and is a

R13 or R22 is absent When any of the bonds to the ammo

nitrogen containing rings as shoWn in formulas (HA) and

nium nitrogen is unsaturated, and R13 or R22 is a straight chain

(IIB).

or branched alkyl group of four carbons or feWer When all of
the bonds to the ammonium nitrogen are saturated.

R3 R4’ R5 R6’ R7’ R8’ R9’ R10’ R11’ aHdRIZ OrRl4’ R15’ R16’

(HA)

R17, R18, R19, R20, and R21, When present, are each indepen
dently selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, heterocyclic, substituted heterocyclic, halo,

(11B)
20

cyano, nitro, or R4 and R5 together With A1 and A2, or R5 and
R7 together With A2 and A3, or R15 and R16 together With A6
and A7, or R1 6 and R1 8 together WithA7 andA8 independently
form a three to eight member cyclolkane, substituted cycloal

kane, cycloalkene, substituted cycloalkene, aryl, substituted
aryl, heterocycle With one to three hetero atoms of nitrogen,
oxygen or sulfur in the ring, or substituted heterocycle With
25

one to three hetero atoms of nitrogen, oxygen or sulfur in the

ring; and When all of the bonds to the ring ammonium nitro

Al is carbon, nitrogen, sulfur or oxygen, provided that
WhenAl is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R3 is absent, and When A1 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

gen are saturated, then any ofR3, R4, R5, R6, R7, R8, R9, R10,
R11’ R12’ R13’ R14’ R15’ R16’ R17’ R18’ R19’ R20’ R21 or R22
30

nitrogen, both R3 and R4 are absent.
A2 is carbon, nitrogen, sulfur or oxygen, provided that
When A2 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R5 is absent, and When A2 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

35

nitrogen, both R5 and R6 are absent.
A3 is carbon, nitrogen, sulfur or oxygen, provided that
When A3 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R7 is absent, and When A3 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

subject in need thereof.
In another embodiment, a method is provided for prevent
40

Chorea, Parkinson’s disease, AlZheimer’s disease, and
related conditions, comprising administering a therapeuti
cally effective amount of a compound as described above to a
45

oxygen or joins a ring atom With an unsaturated bond and is a

50

In another embodiment, a method is provided for prevent
administering a therapeutically effective amount of a com
55

oxygen or joins a ring atom With an unsaturated bond and is a

nitrogen, both R18 and R19 are absent.

pound as described above to a mammalian subject in need
thereof.

Other methods, features and advantages of the present
invention Will be or become apparent to one With skill in the

60

nitrogen, both R16 and R17 are absent.
A8 is carbon, nitrogen, sulfur or oxygen, provided that
When A8 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R18 is absent, and When A8 is sulfur or

pound as described above to a mammalian subject in need
thereof.

ing and/ or treating gastrointestinal tract disorders comprising

nitrogen, both R14 and R15 are absent.
A7 is carbon, nitrogen, sulfur or oxygen, provided that
When A7 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R16 is absent, and When A7 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

mammalian subject in need thereof.
In another embodiment, a method is provided for prevent
ing and/or treating substance use and/or abuse comprising
administering a therapeutically effective amount of a com

A6 is carbon, nitrogen, sulfur or oxygen, provided that
When A6 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R14 is absent, and When A6 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

ing and/ or treating a central nervous system associated disor

der, for example, schizophrenia, Tourettes’, Huntington’s

nitrogen, both R9 and R10 are absent.
A5 is carbon, nitrogen, sulfur or oxygen, provided that
When A5 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R11 is absent, and When A5 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a
nitrogen, both R1 1 and R12 are absent.

tively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective
amount of a compound as described above to a mammalian

nitrogen, both R7 and R8 are absent.
A4 is carbon, nitrogen, sulfur or oxygen, provided that
When A4 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R9 is absent, and When A4 is sulfur or

Which is attached to the ammonium nitrogen is a straight or
branched alkyl group of four carbons or feWer.
In another embodiment, a composition is provided com
prising a pharmaceutically acceptable carrier and a com
pound as described above.
In another embodiment, a method is provided for selec

art upon examination of the folloWing detailed descriptions. It
is intended that all such additional methods, features and
advantages be included Within this description, be Within the
scope of the present invention, and be protected by the accom

panying claims.
DETAILED DESCRIPTION OF INVENTION
65

Before the present compositions and methods are
described, it is to be understood that the invention is not

US 8,178,678 B2
5

6

limited to the particular methodologies, protocols, assays,

alkynyl” refers to alkynyl moieties further bearing one or

and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to

more substituents as set forth above.

The term “aryl” refers to aromatic groups having 6 to 24
carbon atoms, and “substituted aryl” refers to aryl groups

describe particular embodiments of the present invention, and
is in no Way intended to limit the scope of the present inven
tion as set forth in the appended claims.
It must be noted that as used herein and in the appended

The term “alkylaryl” refers to alkyl-substituted aryl
groups, and “substituted alkylaryl” refers to alkylaryl groups

claims, the singular forms “a,” “an,” and “the” include plural

further bearing one or more substituents as set forth above.

references unless the context clearly dictates otherWise.
Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meanings as commonly under
stood by one of ordinary skill in the art to Which this invention
belongs. All publications cited herein are incorporated herein

The term “arylalkyl” refers to aryl-substituted alkyl
groups, and “substituted arylalkyl” refers to arylalkyl groups

further bearing one or more substituents as set forth above.

further bearing one or more substituents as set forth above.

The term “arylalkenyl” refers to aryl-substituted alkenyl
groups, and “substituted arylalkenyl” refers to arylalkenyl

by reference in their entirety for the purpose of describing and

groups further bearing one or more substituents as set forth

disclosing the methodologies, reagents, and tools reported in

above.

the publications that might be used in connection With the

The term “arylalkynyl” refers to aryl-substituted alkynyl
groups, and “substituted arylalkynyl” refers to arylalkynyl

invention. Nothing herein is to be construed as an admission

that the invention is not entitled to antedate such disclosure by

groups further bearing one or more substituents as set forth

virtue of prior invention.
The term “nicotinic acetylcholine receptor” refers to the

above.
The term “heterocyclic” refers to cyclic moieties contain

20

endogenous acetylcholine receptor having binding sites for

ing one or more heteroatoms as part of the ring structure and

acetylcholine Which also bind to S-nicotine. The term “nico

having 3 to 24 carbon atoms, and “substituted heterocyclic”

tinic acetylcholine receptor” includes the term “neuronal

refers to heterocyclic moieties further bearing one or more
substituents as set forth above.

nicotinic acetylcholine receptor.”
The terms “subtype of nicotinic acetylcholine receptor,”
and “nicotinic acetylcholine receptor subtype” refer to vari

25

ous subunit combinations of the nicotinic acetylcholine
receptor, and may refer to a particular homomeric or hetero
meric complex, or multiple homomeric or heteromeric com

plexes.

The term “acyl” refers to alkyl-carbonyl groups, and “sub
stituted acyl” refers to acyl groups further bearing one or
more substituents as set forth above.

30

The term “halogen” refers to ?uoride, chloride, bromide or
iodide groups.
It is understood that in all substituted groups de?ned above,

The term “agonist” refers to a substance Which interacts
With a receptor and increases or prolongs a physiological

polymers arrived at by de?ning sub stituents With further sub
stituents to themselves (e. g. substituted aryl having a substi

response (i.e. activates the receptor).

tuted aryl group as a substituent Which is itself substituted
With a substituted aryl group, etc.) are not intended for inclu
sion herein. In such cases, the maximum number of such
substituents is three. That is to say that each of the above

The term “partial agonist” refers to a substance Which
interacts With and activates a receptor to a lesser degree than
an agonist.
The term “antagonist” refers to a substance Which interacts
With and decreases the extent or duration of a physiological
response of that receptor.
The terms “disorder,” “disease,” and “condition” are used
inclusively and refer to any status deviating from normal.
The term “central nervous system associated disorders”

35

de?nitions is constrained by a limitation that, for example,
substituted aryl groups are limited to -substituted aryl-(sub

stituted aryl)-sub stituted aryl.
40

Compounds of the present invention are bis-quaternary
ammonium salts corresponding to Formula (I):

45

ganic anion.
Q is selected from phenylene, biphenylene, 4CH:CHi,
4CH:CH4CH:CHi, iCECi, 4CECiCECi,
4Oi(CH2)24Oi, and 4OiCH2)2iO(CH2)24Oi.

50

stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substi
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substi
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalky
nyl, substituted arylalkynyl, heterocyclic, substituted

55

heterocyclic; SOYl, SOZYI, SOZOYl or SO2NHYl, WhereYl

includes any cognitive, neurological, and mental disorders
causing aberrant or pathological neural signal transmission,
such as disorders associated With the alteration of normal
neurotransmitter release in the brain.
The term “loWer alkyl” refers to straight or branched chain

alkyl radicals having in the range of l to 4 carbon atoms.
The term “alkyl” refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and “substituted alkyl”

XIQ and X2© are each independently an organic or inor

L1 and L2 are each independently selected from alkyl, sub

refers to alkyl radicals further bearing one or more substitu

ents including, but not limited to, hydroxy, alkoxy (of a loWer

alkyl group), mercapto (of a loWer alkyl group), aryl, hetero
cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car
boxyl, carbarnate, sulfonyl, and sulfonamide.

is selected from hydrogen, loWer alkyl, alkenyl, alkynyl or
aryl, and where Y1 is not hydrogen in SOYl and if Y1 is
alkenyl or alkynyl, the site of unsaturation is not conjugated
With a heteroatom; COY2, Where Y2 is selected from hydro

The term “cycloalkyl” refers to cyclic ring-containing moi
eties containing 3 to 8 carbon atoms, and “substituted
cycloalkyl” refers to cycloalkyl moieties further bearing one
or more substituents as set forth above.

The term “alkenyl” refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon double
bond and having 2 to 19 carbon atoms, and “substituted
alkenyl” refers to alkenyl groups further bearing-one or more

60

substituents as set forth above.

The term “alkynyl” refers to straight or branched chain

hydrocarbyl moieties having at least one carbon-carbon triple
bond and having 2 to 19 carbon atoms, and “substituted

gen, alkyl, substituted alkyl, cycloalkyl, substituted

cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub
stituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, sub
stituted alkylaryl, arylalkyl, substituted arylalkyl, arylalk
enyl, substituted arylalkenyl, arylalkynyl, substituted
65

arylalkynyl, heterocyclic, or substituted heterocyclic, and
Where if Y2 comprises alkenyl or alkynyl, the site of unsat
uration is not conjugated With the carbonyl group; 0Y3,

US 8,178,678 B2
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7
Where Y3 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk

A5 is carbon, nitrogen, sulfur or oxygen, provided that
When A5 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R11 is absent, and When A5 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or

nitrogen, both R11 and R12 are absent.
A6 is carbon, nitrogen, sulfur or oxygen, provided that

substituted heterocyclic, Where if Y3 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated With the
oxygen; NY4Y5, Where Y4 and Y5 are each independently

When A6 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R14 is absent, and When A6 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted

When A7is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R16 is absent, and When A7 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

nitrogen, both R14 and R15 are absent.
A7 is carbon, nitrogen, sulfur or oxygen, provided that

nitrogen, both R16 and R17 are absent.
A8 is carbon, nitrogen, sulfur or oxygen, provided that

heterocyclic, Where ifY4 orY5 comprises alkenyl or alkynyl,

When A8 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R18 is absent, and When A8 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

the site of unsaturation is not conjugated With the nitrogen;

SY6, Where Y6 is selected from hydrogen, alkyl, substituted

alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi
tuted arylalkynyl, heterocyclic, or substituted heterocyclic,
and Where if Y6 comprises alkenyl or alkynyl, the site of
unsaturation is not conjugated With the sulfur.
R1 and R2 are each independently ?ve or six membered

20

nitrogen, both R18 and R19 are absent.
A9 is carbon, nitrogen, sulfur or oxygen, provided that
When A9 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R20 is absent, and When A9 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

25

nitrogen, both R20 and R21 are absent.
R13 or R22 is absent When any of the bonds to the ammo

nium nitrogen is unsaturated, and R13 or R22 is a straight chain

nitrogen containing rings as shoWn in formulas (HA) and

or branched alkyl group of four carbons or feWer When all of
the bonds to the ammonium nitrogen are saturated.

(HB).
30

35

40

R3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ and R12’ or R14’ R15’
R16, R17, R18, R19, R20, and R21, When present, are each
independently selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi
tuted arylalkynyl, heterocyclic, substituted heterocyclic,
halo, cyano, nitro, or R4 and R5 together WithAl and A2, or R5
and R7 together With A2 and A3 , or R15 and R16 together With
A6 and A7, or R16 and R18 together With A7 and A8 indepen
dently form a three to eight member cyclolkane, substituted

cycloalkane, cycloalkene, substituted cycloalkene, aryl, sub
45

R7’ R8’ R9’ R10’ R11’ R12’ R13’ R14’ R15’ R16, R17’ R18, R19’

Al is carbon, nitrogen, sulfur or oxygen, provided that
WhenAl is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R3 is absent, and When A1 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

R20, R21 or R22 Which is attached to the ammonium nitrogen
50

Zole, imidaZole, oxaZole, isoxaZole, thiaZole, isothiaZole,
oxadiaZole, oxatriaZole, dioxaZole, 1,2,3-triazole, 1,2,4-tria

55

oxygen or joins a ring atom With an unsaturated bond and is a

nitrogen, both R5 and R6 are absent.
A3 is carbon, nitrogen, sulfur or oxygen, provided that
When A3 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R7 is absent, and When A3 is sulfur or
oxygen or joins a ring atom With an unsaturated bond and is a

is a straight or branched alkyl group of four carbons or feWer.

For example, R1 and R2 include pyrrole, pyrrolidine, pyra

nitrogen, both R3 and R4 are absent.
A2 is carbon, nitrogen, sulfur or oxygen, provided that
When A2 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R5 is absent, and When A2 is sulfur or

stituted aryl, heterocycle With one to three hetero atoms of
nitrogen, oxygen or sulfur in the ring, or substituted hetero
cycle With one to three hetero atoms of nitrogen, oxygen or
sulfur in the ring; and When all of the bonds to the ring
ammonium nitrogen are saturated, then any of R3 , R4, R5 , R6,

60

Zole, pyridine, pyrimidine, piperidine, quinoline, tetrahydro
quinoline, isoquinoline, tetrahydroisoquinoline, pyraZine,
piperaZine, pyridaZine, triaZine, oxaZine, phenaZine, pteri
dine, benZoxaZine, phthalaZine, naphthridine, quinoxaline,
quinaZoline, cinnoline, quinuclidine, benZothiaZole, ben
ZisoxaZole, benZoxaZole, indaZole, pyranopyrrole, cyclopen
tapyridine, benZimidaZole, isoindole, 3H-indole, indolene
and triaZine.

oxygen or joins a ring atom With an unsaturated bond and is a

As another example, R3, R4, R5, R6, R7, R8, R9, R10, R11,
R12’ R14’ R15’ R16’ R17’ R18’ R19’ R20’ and R21’ include
hydrogen, methyl, ethyl, propyl, butyl, hydroxymethyl,
hydroxyethyl, hydroxypropyl, tri?uoromethyl, chloro,
bromo, phenyl, pyrrolidine, N-alkyl pyrrolidine (for example

nitrogen, both R9 and R10 are absent.

Where the alkyl chain is methyl, ethyl or propyl), unsaturated

nitrogen, both R7 and R8 are absent.
A4 is carbon, nitrogen, sulfur or oxygen, provided that
When A4 is a carbon and joins a ring atom With an unsaturated
bond or is a nitrogen, R9 is absent, and When A4 is sulfur or

65
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pyrrolidine, unsaturated N-alkyl pyrrolidine (for example

In a compound of Formula (I), preferably R3, R4, R5, R6,

Where the alkyl chain is methyl, ethyl or propyl), aZiridine,

R7, R8, R9, R10, R11 or R12 is absent or is hydrogen, alkyl,
hydroxyalkyl, halo, phenyl or l-alkyl-2-pyrrolidinyl. More

N-methyl aZiridine, aZetidine, N-methyl aZetidine, unsatur
ated aZetidine, unsaturated N-methyl aZetidine, piperidine,
N-methyl piperidine, unsaturated piperidine, unsaturated

preferably, R3, R4, R5, R6, R7, R8, R9, R10, R11 or R12 is absent
or is hydrogen, methyl, ethyl, propyl, butyl, hydroxymethyl,
hydroxyethyl, hydroxypropyl, bromo, phenyl or l-methyl-2

N-methyl piperidine, aZepane, N-methyl aZepane, unsatur

pyrrolidinyl.

ated aZepane, unsaturated N-methyl aZepane, aZocane,
N-methyl aZocane, unsaturated aZocane, unsaturated N-me

In a compound of Formula (I), preferably Q is phenylene,
biphenylene, iCH:CH4CH:CHi, iC5C4CECi
and iOi(CH2)2iOi(CH2)2A)i.

thyl aZocane, l-aZa-bicyclo[3.2.l]octane, l-aZa-bicyclo
[2.2.1]heptane, 8-methyl-8-aZa-bicyclo[3.2.l]octane, l-aZa

In a compound of Formula (I), preferably L1 and L2 are the
same and are 4CH2i, i(CH2)2i, i(CH2)3i,

tricyclo [3.3.1.13 ’7]decane, methyl cycloalkyl, methyl
substituted cycloalkyl, methyl pyrrolidine, methyl N-alkyl

i(CH2)4i, %ECi, %H2%ECi or i(CH2)2i

pyrrolidine (for example Where the alkyl chain is methyl,
ethyl or propyl), methyl unsaturated pyrrolidine, methyl
unsaturated N-alkyl pyrrolidine (for example Where the alkyl
chain is methyl, ethyl or propyl), methyl aZiridine, methyl
N-methyl aZiridine, methyl aZetidine, methyl N-methyl aZe
tidine, methyl unsaturated aZetidine, methyl unsaturated

CECi

In a compound of Formula (I), referablyQXlQ and X2©
are halogens. More preferably, X1
bromide.

20

aZepane, methyl unsaturated aZepane, methyl unsaturated
N-methyl aZepane, methyl aZocane, methyl N-methyl aZo
cane, methyl unsaturated aZocane, methyl unsaturated N-me

thyl aZocane, methyl-l-aZa-bicyclo[3.2.l]octane, methyl-l

aZa-bicyclo[2.2.l]heptane,

25

8-methyl-8-aZa-bicyclo[3.2.l]

methyl, R5 is hydrogen, methyl, ethyl, butyl, phenyl, l-me
thyl-2-pyrrolidinyl, bromo, hydroxymethyl or hydroxypro
30

thiophene, benZo[c]thiophene, indole, indolenine, isoindole,
cyclopental[b]pyridine, pyrano[3,4-b]pynrole, indaZole,
indoxaZine, benZoxaZole, anthranil, naphthalene, tetralin,
decalin, chromene, coumarin, chroman-4-one, isocoumarin,
isochromen-3-one, quinoline, isoquinoline, cinnoline,
quinaZoline, naphthyrdine, pyrido[3,4-b]-pyridine, pyridol
[3,2-b]pyridine, pyrido[4,3,-b]-pyridine, benZoxaZine,
anthracene, phenanthrene, phenalene, ?uorene, caraZole,
xanthene, acnidine, octahydro-[l]pyridine, l-methyloctahy
dro-[l]pyridine, octahydroindole, l-methyloctahydro-in
dole, octahydro-cyclopenta[b]pyrrole, l-methyloctahydro
cyclopenta[b]pyrrole,
decahydroquinoline,
and

l -met<l5yldecahydroquinoline.
X1 and X2©, for example,

In another embodiment, the compound of Formula (I) is
de?ned Wherein -Ll-Q-L2- is i(CH2)4-l,2-phenylene
(CH2)4*> *(CH2)4'1>3'Pheny1ene'(CH2 4*: *(CH2)3'1,
35

40

Exemplary compounds of the present invention include:
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-[3 -(2'-S- l -

methyl-pyrrolidin-2 -yl)-pyridinium]dibromide;
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(2-methyl

pyridinium) dibromide;

maleate, tartrate, oxalate, succinate, or similar pharmaceuti

55

cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(3 -methyl

pyridinium) dibromide;
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(4-methyl

pyridinium) dibromide;
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(5 ,6,7,8-tet

cally acceptable organic acid addition salts, including the

rahydro -quinolinium)dibromide;
cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(5 ,6,7,8-tet

rahydro -isoquinolinium)dibromide;

pharmaceutically acceptable salts listed in the Journal of
Pharmaceutical Sciences volume 66, page 2, 1977, Which are

cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(2,4-dim

ethyl-pyridinium) dibromide;

hereby incorporated by reference. The above salt forms may
60

cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(3 ,4-dim

ethyl-pyridinium) dibromide;

solvents.

In a compound of Formula (I), preferably R1 and R2 are

cis-cis-N,N'-(dodeca-5 ,7-diene-l , l 2-diyl)-bis-(3 ,5 -dim

substituted, six-membered, aromatic rings. More preferably,
R1 and R2 are substituted pyridinium rings. In other preferred

embodiments, R1 and R2 are quinoline, isoquinoline, tetrahy

(CH2)2*,
i(CH2)2iCEC-l ,3 -phenylene-CECi
(CH2)2*,
iCHziCgC-l ,4-phenylene-CECH2i,
4CEC-4,4'-biphenylene-C:CECi,
i(CH2)3i
CH:CHiCH:CHi(CH2)3i,
i(CH2)34CECi

are chloride or bromide.
45

50

droquinoline or tetrahydroisoquinoline.
In a compound of Formula (I), preferably R13 is absent.

4-phenylene-(CH2)3i,
i(CH2)2-4,4'-biphenylene
(CH2)2*,
i(CH2)2iCEC-l ,2-phenylene-CECi

O4CH2i, R1 and R2 are quinoline, isoquinoline,
tetrahydroquinoline or tetrahydroisoquinoline, and X1 and X2

include F', Cl“, Br“, I“,
N02“, HSO4_, SO4_, HPO4_, PO42“, methanesulfonate, tri
?uromethane sulfate, p-toluenesulfonate, benZenesulfonate,
salicylate, proprionate, ascorbate, aspartate, fumarate, galac
tarate, maleate, citrate, glutamate, glycolate, lactate, malate,

be in some cases hydrates or solvates With alcohols and other

pyl, R7 is hydrogen or methyl, R9 is hydrogen or methyl, R1 1
is hydrogen, and X1 and X2 are chloride or bromide.

further may be substituted With one or more substituents. For

example, possible rings include benZene, pyridine, pyran,
indene, isoindene, benZofuran, isobenZofuran, benZo [b]

(CH2)4*s *(CH2)4'1s3'Pheny1ene'(CH2)4*s i(CH2)3_1s
4-phenylene-(CH2)3i,
i(CH2)2-4,4'-biphenylene
(CH2)2i,
i(CH2)2iCEC-l ,2-phenylene-CECi
(CH2)2i,
i(CH2)2iCEC-l ,3 -phenylene-CECi
(CH2)2i, 4CH24CEC-l ,4-phenylene-CECiCH2i,
4CEC-4,4'-biphenylene-CECi, i(CH2)34CH:CHi
CH:CHi(CH2)3i,
i(CH2)3iC5C4CECi
(CH2)3* or 4CH24O*(CH2)2*O*(CH2)2*O*
CHzi, R1 and R2 are pyridinium rings, R3 is hydrogen or

octane, and methyl-l -aZa-tricyclo[3.3 .l .l3’7]decane.
As a further example, When R4 and R5 together WithAl and
A2, or R5 and R7 together With A2 and A3, or R15 and R16
together With A6 and A7, or R16 and R18 together With A7 and
A8 independently form a three to eight-membered ring, that
ring may be a heterocycle containing up to three hetero atoms
(for example nitrogen, oxygen or sulfur) in the ring, and

are chloride or

In another embodiment, the compound of Formula (I) is
de?ned Wherein -Ll-Q-L2- is 4CH2)4-l,2-phenylene

N-methyl aZetidine, methyl piperidine, methyl N-methyl pip
eridine, methyl unsaturated piperidine, methyl unsaturated
N-methyl piperidine, methyl aZepane, methyl N-methyl

and X2

65

ethyl-pyridinium) dibromide;
N,N'- [l ,4-phenylenedi-(4 -butanyl)] -bis-[3-(2'-S-l -methyl
pyrrolidin-2 -yl) -pyridinium] dibromide;
N,N'- [l ,4-phenylenedi-(4 -butanyl)] -bis-(2-methylpyri
dinium) dibromide;

US 8,178,678 B2
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N,N'-(5 ,7-dodecadiyn-1 ,12-diyl)-bis-(4-methylpyridinium)

mitter release. The neurotransmitter affected may include

dopamine, norepinephrine, serotonin, gamma-aminobutryic

dichloride;

N,N'-(5,7-dodecadiyn-1,12-diyl)-bis-(3,4-dimethylpyri
dinium)dichloride;
N,N'-(5,7-dodecadiyn-1,12-diyl)-bis-(3,5 -dimethylpyri
dinium)dichloride;
N,N'-(5,7-dodecadiyn-1,12-diyl)-bis-(5,6,7,8-tetrahydroiso
quinolinium)dichloride;
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(3-methyl-pyri
dinium)dibromide;
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(4-methyl-pyri
dinium)dibromide;
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(5,6,7,8-tetrahy
droisoquiolinium)dibromide;
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(3,4-dimethyl
pyridinium)dibromide;
N,N'-[(1,4-phenylene)-bis-(4-butynyl)]-bis-(3,5 -dimethyl
pyridinium)dibromide;

m

increasing or decreasing the likelihood of ?ring an action
potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

cholinergic response.
In another embodiment, the present invention is directed to
a method for preventing and/or treating a central nervous

system associated disorder comprising administering to a
mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
15

compound of Formula (I) may selectively bind to one or more

subtypes of nicotinic acetylcholine receptor. The compound
of Formula (I) may act as an agoinst or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a

N,N'-[(1,1'-biphenyl)-4,4'-di-(1-propyn-3 -yl)] -bis-(3 -meth

ylpyridinium)dibromide;

acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

20

neurotransmitter from a central nervous system tissue. The

N,N'-[(1,1'-biphenyl)-4,4'-di-(1-propyn-3 -yl)] -bis-(4 -meth

neurotransmitter affected may include dopamine, norepi

ylpyridinium)dibromide;
N,N'-[(1,1'-biphenyl)-4,4'-di-(1-propyn-3-yl)]-bis-(3,4-dim
ethylpyridinium)dibromide.

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.

The compounds of the present invention may contain one

Alternatively, the compound of Formula (I) may act as an

antagonist of nicotinic acetylcholine receptor function.
25

or more stereocenters. The invention includes all possible
diastereomers and all enantiomeric forms as Well as all com

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans
mitter release. The neurotransmitter affected may include

binations of diastereomers and enantiomers, including race
mic mixtures. The compounds can be separated into substan

tially optically pure compounds.

30

line receptor agents. Thus, they may augment or inhibit

[3H]iS-nicotine binding, [3H]MLA binding, evoke or

increasing or decreasing the likelihood of ?ring an action

inhibit neurotransmitter release, and/or evoke or inhibit the
35

Central nervous system disorders Which may be treated

according to the method of the present invention include
40

dal motor function disorders, Parkinson’s disease, progres
45

ation of one or more second messenger systems Within the
cell so as to decrease or increase the nicotinic cholinergic

response.
In one embodiment, the present invention relates to a

method for selectively modulating the function of a nicotinic
acetylcholine receptor comprising administering to a mam
malian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the

50

directed to a method for preventing and/ or treating sub stance
use and/or abuse comprising administering to a mammalian
subject in need thereof a therapeutically effective amount of a

compound of Formula (I). In such a method, the compound of
55

of Formula (I) may act as an agoinst or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a

nicotinic acetylcholine receptor. The compound of Formula
(I) may act as an agoinst or partial agonist of nicotinic ace

tylcholine receptor function. Hence the compound of For
mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue. The

neurotransmitter from a central nervous system tissue. The

neurotransmitter affected may include dopamine, norepi

sive supramolecular palsy, Huntington’s disease, Gilles de la
Tourette syndrome, tardive dyskinesia, neuroendocrine dis
orders, dysregulation of food intake, disorders of nociception,
pain, mood and emotional disorders, depression, panic anxi
ety, psychosis, schiZophrenia, or epilepsy.
In yet another embodiment, the present invention is

Formula (I) may selectively bind to one or more subtypes of

compound of Formula (I) may selectively bind to one or more

subtypes of nicotinic acetylcholine receptor. The compound

AlZheimer’s disease, dementia, cognitive dysfunctions (in
cluding disorders of attention, focus and concentration),
attention de?cit disorders, affective disorders, extrapyrami

change the membrane potential of the cell, thereby increasing
or decreasing the likelihood of ?ring an action potential.
Alternatively, interaction of a compound of the invention With
a postsynaptic acetylcholine receptor may result in the alter

potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

cholinergic response.

at a postsynaptic site, neurotransmitter release per se is not

altered. Rather, the compounds of the invention may act by
interacting With a postsynaptic acetylcholine receptor to

dopamine, norepinephrine, serotonin, gamma-aminobutryic
acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

The compounds of the invention are nicotinic acetylcho

?ux of ions through the nicotinic receptor. Moreover, the
compounds of the invention may act either at presynaptic
sites or postsynaptic sites, for example, at a postsynaptic
acetylcholine receptor containing an (X7 subunit. When acting

Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central

60

neurotransmitter affected may include dopamine, norepi

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.

nephrine, serotonin, gamma-aminobutryic acid, or glutamate.

Alternatively, the compound of Formula (I) may act as an

Alternatively, the compound of Formula (I) may act as an

antagonist of nicotinic acetylcholine receptor function.

antagonist of nicotinic acetylcholine receptor function.

Hence the compound of Formula (I) may decrease the extent

Hence the compound of Formula (I) may decrease the extent

or duration of the release of a neurotransmitter from a central 65 or duration of the release of a neurotransmitter from a central

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans

US 8,l78,678 B2
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mitter release. The neurotransmitter affected may include

may include dopamine, norepinephrine, serotonin, gamma
aminobutryic acid, or glutamate. Alternatively, the compound

dopamine, norepinephrine, serotonin, gamma-aminobutryic
acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

of Formula (I) may act as an antagonist of nicotinic acetyl
choline receptor function. Hence the compound of Formula
(I) may decrease the extent or duration of the release of a
neurotransmitter from a central nervous system tissue, or may
decrease the extent or duration of the release of a neurotrans
mitter from a peripheral nervous system tissue, or may act

increasing or decreasing the likelihood of ?ring an action
potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

cholinergic response.

directly on a non-nervous system tissue. In this regard, the

compound of Formula (I) may act by decreasing stimulant

The conditions of substance use and/or abuse treated

according to the method of the present invention include
nicotine abuse (including use in smoking cessation therapy),

evoked neurotransmitter release. The neurotransmitter

affected may include dopamine, norepinephrine, serotonin,
gamma-aminobutryic acid, or glutamate. Alternatively, the

nicotine intoxication, amphetamine abuse, methamphet
amine abuse, MDMA (methylenedioxymethamphetamine)
abuse, methylphenidate abuse, cocaine abuse, or alcohol

compound of Formula (I) may act by interacting With a

postsynaptic acetylcholine receptor to change the membrane
potential of the cell thereby increasing or decreasing the

abuse.
In another embodiment, the present invention is directed to

likelihood of ?ring an action potential, or to alter one or more
second messenger systems Within the cell so as to decrease or

a method for preventing and/or treating gastrointestinal tract
disorders comprising administering to a mammalian subject
in need thereof a therapeutically effective amount of a com

20

pound of Formula (I). In such a method, the compound of

distress syndrome, allergy, anemia, ankylosing spondylitis,
asthma, atherosclerosis, bacterial infections, benign prostatic

Formula (I) may selectively bind to one or more subtypes of

nicotinic acetylcholine receptor. The compound of Formula
(I) may act as an agonist or partial agonist of nicotinic ace

tylcholine receptor function. Hence the compound of For
mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue, or may increase
or prolong the release of a neurotransmitter from a peripheral
nervous system tissue, or may act directly on a gastrointesti
nal tract tissue. The neurotransmitter affected may include

increase the nicotinic cholinergic response.
In?ammatory disorders Which may be treated according to
the method of the present invention include adult respiratory

25

hyperplasia, cholecystitis, ulcerative colitis, Crohn’s disease,
diabetes mellitus, emphysema, gastritis, glomerulonephritis,
hypereosinophilia, irritable boWel syndrome, multiple scle
rosis, osteoarthritis, pancreatitis, polymyositis, psoriasis and
rheumatoid arthritis.
The compounds of the present invention can be delivered

30

dopamine, norepinephrine, serotonin, gamma-aminobutryic

directly or in pharmaceutical compositions along With suit
able carriers or excipients, as is Well knoWn in the art. For

acid, or glutamate. Alternatively, the compound of Formula

example, a pharmaceutical composition of the invention may

(I) may act as an antagonist of nicotinic acetylcholine recep
tor function. Hence the compound of Formula (I) may

include a conventional additive, such as a stabiliZer, buffer,

salt, preservative, ?ller, ?avor enancer and the like, as knoWn

decrease the extent or duration of the release of a neurotrans 35 to those skilled in the art. Exemplary buffers include phos
mitter from a central nervous system tissue, or may decrease
phates, carbonates, citrates and the like. Exemplary preserva
the extent or duration of the release of a neurotransmitter from
tives include EDTA, EGTA, BHA, BHT and the like.
An effective amount of such agents can readily be deter
a peripheral nervous system tissue, or may act directly on a

gastrointestinal tract tissue. In this regard, the compound of
Formula (I) may act by decreasing stimulant-evoked neu

40

mined by routine experimentation, as can the most effective
and convenient route of administration and the most appro

priate formulation. Various formulations and drug delivery

rotransmitter release. The neurotransmitter affected may

include dopamine, norepinephrine, serotonin, gamma-ami

systems are available in the art. See, e.g., Gennaro, A. R., ed.

nobutryic acid, or glutamate. Alternatively, the compound of

(1995) Remington’s Pharmaceutical Sciences.
Suitable routes of administration may, for example,

Formula (I) may act by interacting With a postsynaptic ace

tylcholine receptor to change the membrane potential of the
cell thereby increasing or decreasing the likelihood of ?ring

45

include oral, rectal, transmucosal, nasal, or intestinal admin

istration and parenteral delivery, including intramuscular,

an action potential, or to alter one or more second messenger

subcutaneous, intramedullary injections, as Well as intrathe

systems Within the cell so as to decrease or increase the

cal, direct intraventricular, intravenous, intraperitoneal, intra

nicotinic cholinergic response.
Gastrointestinal disorders Which may be treated according

50

to the method of the present invention include irritable boWel

syndrome, colitis, diarrhea, constipation, gastric acid secre
tion or ulcers.

In yet another embodiment, the present invention is
directed to a method for preventing and/ or treating in?am
matory tract disorders comprising administering to a mam

55

may be manufactured by any of the methods Well-knoWn in

the art, such as by conventional mixing, dissolving, granulat

ing, dragee-making, levigating, emulsifying, encapsulating,

compound of Formula (I) may selectively bind to one or more
60

entrapping, or lyophiliZing processes. As noted above, the

65

more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of admin

of Formula (I) may act as an agonist or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a
neurotransmitter from a central nervous system tissue, or may
increase or prolong the release of a neurotransmitter from a
peripheral nervous system tissue, or may act directly on a
non-nervous system tissue. The neurotransmitter affected

system, such as a depot or sustained release formulation.

The pharmaceutical compositions of the present invention

malian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the

subtypes of nicotinic acetylcholine receptor. The compound

nasal, or intraocular injections. In addition, the agent or com
position thereof may be administered sublingually or via a
spray, including a sublingual tablet or a sublingual spray. The
agent or composition thereof may be administered in a local
rather than a systemic manner. For example, a suitable agent
can be delivered via injection or in a targeted drug delivery

compositions of the present invention can include one or

istration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in physi

US 8,178,678 B2
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ologically compatible buffers such as Hanks’ solution, Ring

unit may be determined by providing a valve to deliver a

er’ s solution, or physiological saline buffer. For transmucosal
or nasal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants
are generally knoWn in the art. In a preferred embodiment of
the present invention the present compounds are prepared in

metered amount. Capsules and cartridges of, for example,

a formulation intended for oral administration. For oral

injection, e. g., by bolus injection or continuous infusion can

gelatin, for use in an inhaler or insuf?ator may be formulated.

These typically contain a poWder mix of the compound and a
suitable poWder base such as lactose or starch.

Compositions formulated for parenteral administration by

administration, the compounds can be formulated readily by
combining the active compounds With pharmaceutically

be presented in unit dosage form, e.g., in ampoules or in
multi-dose containers, With an added preservative. The com
positions may take such forms as suspensions, solutions, or
emulsions in oily or aqueous vehicles, and may contain for

acceptable carriers Well knoWn in the art. Such carriers enable
the compounds of the invention to be formulated as tablets,

pills, dragees, capsules, liquids, gels, syrups, slurries, suspen

mulatory agents such as suspending, stabiliZing and/or dis
persing agents. Formulations for parenteral administration

sions and the like, for oral ingestion by a subject. The com
pounds may also be formulated in rectal compositions such as

include aqueous solutions or other compositions in Water
soluble form.

suppositories or retention enemas, e.g., containing conven
tional suppository bases such as cocoa butter or other glyc
erides.
Pharmaceutical preparations for oral use canbe obtained as

Suspensions of the active compounds may also be prepared

as appropriate oily injection suspensions. Suitable lipophilic
solvents or vehicles include fatty oils such as sesame oil and

solid excipients, optionally grinding a resulting mixture, and
processing the mixture of granules, after adding suitable aux

20

iliaries, if desired, to obtain tablets or dragee cores. Suitable

excipients are, in particular, ?llers such as sugars, including
lactose, sucrose, mannitol, or sorbitol; cellulose preparations
such as, for example, maiZe starch, Wheat starch, rice starch,

potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcel
lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin

ers or agents that increase the solubility of the compounds to
25

alloW for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in poWder form for
constitution With a suitable vehicle, e.g., sterile pyrogen-free

tegrating agents may be added, such as the cross-linked poly

Water, before use.

As mentioned above, the compositions of the present

vinyl pyrrolidone, agar, or alginic acid or a salt thereof such as

sodium alginate. Also, Wetting agents such as sodium dodecyl

synthetic fatty acid esters, such as ethyl oleate or triglycer
ides, or liposomes. Aqueous injection suspensions may con
tain substances that increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabiliZ

30

invention may also be formulated as a depot preparation.

sulfate may be included.

Such long acting formulations may be administered by

Dragee cores are provided With suitable coatings. For this
purpose, concentrated sugar solutions may be used, Which

implantation (for example, subcutaneously or intramuscu

may optionally contain gum arabic, talc, polyvinyl pyrroli
done, carbopol gel, polyethylene glycol, and/or titanium

larly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated With suitable poly
35

dioxide, lacquer solutions, and suitable organic solvents or
solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identi?cation or to characteriZe

different combinations of active compound doses.
Pharmaceutical preparations for oral administration
include push-?t capsules made of gelatin, as Well as soft,
sealed capsules made of gelatin and a plasticiZer, such as
glycerol or sorbitol. The push-?t capsules can contain the
active ingredients in admixture With ?ller such as lactose,
binders such as starches, and/or lubricants such as talc or

magnesium stearate and, optionally, stabiliZers. In soft cap
sules, the active compounds may be dissolved or suspended in
suitable liquids, such as fatty oils, liquid paraf?n, or liquid
polyethylene glycols. In addition, stabiliZers may be added.
All formulations for oral administration should be in dosages
suitable for such administration.
In one embodiment, the compounds of the present inven
tion can be administered transdermally, such as through a skin
patch, or topically. In one aspect, the transdermal or topical
formulations of the present invention can additionally com
prise one or multiple penetration enancers or other effectors,
including agents that enhance migration of the delivered com
pound. Transderrnal or topical administration could be pre

ferred, for example, in situations in Which location speci?c
delivery is desired.
For administration by inhalation, the compounds for use

Suitable carriers for the hydrophobic molecules of the
invention are Well knoWn in the art and include co-solvent
40

45

of the nonpolar surfactant polysorbate 80, and 65% W/v poly
ethylene glycol 300, made up to volume in absolute ethanol.
The VPD co-solvent system (VPDzSW) consists of VPD
diluted 1:1 With a 5% dextrose in Water solution. This co

solvent system is effective in dissolving hydrophobic com

pounds and produces loW toxicity upon systemic administra
50

tion. Naturally, the proportions of a co-solvent system may be

varied considerably Without destroying its solubility and tox
icity characteristics. Furthermore, the identity of the co-sol
vent components may be varied. For example, other loW
toxicity nonpolar surfactants may be used instead of
55

polysorbate 80, the fraction siZe of polyethylene glycol may
be varied, other biocompatible polymers may replace poly
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars
or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic mol
60

ecules may be employed. Liposomes and emulsions are Well
knoWn examples of delivery vehicles or carriers for hydro

phobic drugs. Liposomal delivery systems are discussed
above in the context of gene-delivery systems. Certain
organic solvents such as dimethylsulfoxide also may be

packs or a nebuliZer, With the use of a suitable propellant, e.g.,

dichlorodi?uoromethane, trichloro?uoromethane, dichlo

systems comprising, for example, benZyl alcohol, a nonpolar
surfactant, a Water-miscible organic polymer, and an aqueous
phase. The co-solvent system may be the VPD co-solvent
system. VPD is a solution of 3% W/v benZyl alcohol, 8% W/v

according to the present invention are conveniently delivered
in the form of an aerosol spray presentation from pressurized

rotetra?uoroethane, carbon dioxide, or any other suitable gas.
In the case of a pressurized aerosol, the appropriate dosage

meric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.

65

employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sus
tained-release systems, such as semi-permeable matrices of
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solid hydrophobic polymers containing the effective amount

skilled in the art from the foregoing description. Such modi
?cations fall Within the scope of the appended claims.

of the composition to be administered. Various sustained
release materials are established and available to those of skill

in the art. Sustained-release capsules may, depending on their
chemical nature, release the compounds for a feW Weeks up to
over 100 days. Depending on the chemical nature and the

Example 1

biological stability of the therapeutic reagent, additional
strategies for stabiliZation may be employed.

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7
diene-1 , 12-diyl)-bis- [3 -(2'-S-1-methyl-pyrrolidin-2

yl)-pyridinium]dibromide

For any composition used in the present methods of treat
ment, a therapeutically effective dose can be estimated ini

tially using a variety of techniques Well knoWn in the art. For
example, in a cell culture assay, a dose can be formulated in
animal models to achieve a circulating concentration range

that includes the 1C5O as determined in cell culture. Dosage
ranges appropriate for human subjects can be determined, for
example, using data obtained from cell culture assays and
other animal studies.
A therapeutically effective dose of an agent refers to that
amount of the agent that results in amelioration of symptoms
or a prolongation of survival in a subject. Toxicity and thera
peutic ef?cacy of such molecules can be determined by stan
dard pharmaceutical procedures in cell cultures or experi

mental animals, e. g., by determining the LD5O (the dose lethal
to 50% of the population) and the ED5O (the dose therapeuti
cally effective in 50% of the population). The dose ratio of

/
Br

Br

/
+

—>

20

\

I

/

N

\CH3

N
25

N/CH3

toxic to therapeutic effects is the therapeutic index, Which can
be expressed as the ratio LDSO/EDSO. Agents that exhibit high
therapeutic indices are preferred.

\

/

/ @ NW

Dosages preferably fall Within a range of circulating con
centrations that includes the ED5O With little or no toxicity.

Dosages may vary Within this range depending upon the
dosage form employed and the route of administration uti
liZed. The exact formulation, route of administration, and
dosage should be chosen, according to methods knoWn in the
art, in vieW of the speci?cs of a subject’s condition.
The amount of agent or composition administered Will, of
course, be dependent on a variety of factors, including the sex,

age, and Weight of the subject being treated, the severity of the

35

40

the prescribing physician.
The present compositions may, if desired, be presented in a
pack or dispenser device containing one or more unit dosage
forms containing the active ingredient. Such a pack or device
may, for example, comprise metal or plastic foil, such as a

45

blister pack. The pack or dispenser device may be accompa
nied by instructions for administration. Compositions com
prising a compound of the invention formulated in a compat
ible pharmaceutical carrier may also be prepared, placed in an
appropriate container, and labeled for treatment of an indi
cated condition.
These and other embodiments of the present invention Will

50

disclosure herein, and are speci?cally contemplated.

\ /

H3C—N

af?iction, the manner of administration, and the judgment of

readily occur to those of ordinary skill in the art in vieW of the

N@—

cis-cis-1,12-Dibromo-dodeca-5,7-diene (1 mmol) Was
added to a solution of S-nicotine (3 mmol) in acetonitrile and
the solution re?uxed for 24 hours. The acetonitrile Was
removed in vacuum and the resulting residue Was partitioned
betWeen ether and Water. The aqueous layer Was Washed
extensively With ether until no S-nicotine left in the aqueous

layer. The resulting aqueous solution of the product Was lyo

philiZed to yieldthe pure product. (70%). lHNMR (300 MHZ,
D20, ppm) 8.60 (s, 2H), 8.59 (d, 2H), 8.32 (d, 1:84, 2H), 7.88
(t, 1:57, 2H), 6.12-6.20 (m, 2H), 5.30-5.40 (m, 2H), 4.43 (t,
J:7.2, 4H), 3.39 (t, 1:84, 2H), 3.01-3.06 (m, 2H), 2.16-2.34
(m, 4H), 2.01-2.09 (m, 10H), 1.64-1.88 (m, 10H), 1.25 (p,
1:75, 4H). l3CNMR, 144.67, 143.35, 132.20, 128.45,
124.12, 67.65, 62.05, 56.65, 39.41, 33.76, 30.32, 26.34,
25.47, 22.36.

Example 2

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7
diene-1 ,12-diyl)-bis-(2-methyl-pyridinium)dibro

55

mide

EXAMPLES

The invention is further understood by reference to the
folloWing examples, Which are intended to be purely exem
plary of the invention. The present invention is not limited in
scope by the exempli?ed embodiments, Which are intended as

60

Br

illustrations of single aspects of the invention only. Any meth
ods that are functionally equivalent are Within the scope of the
invention. Various modi?cations of the invention in addition
to those described herein Will become apparent to those

Br

65
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-continued

/

/ (3N

/

(p, 1:75, 4H), 1.25 (p, 1:75, 4H). l3cNMR, 145.99, 143.71,
141.30, 139.95, 132.19, 127.46, 124.06, 61.69, 30.27, 26.35,

_

N®

213,6

25.44, 17.93.

\ /

Example 4

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7
diene-1 ,12-diyl)-bis-(4-methyl-pyridinium)dibro

cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a

solution of 2-picoline (3 mmol) in acetonitrile and the solu

mide

tion re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively

With ether until no picoline left in the aqueous layer. The
resulting aqueous solution of the product Was lyophiliZed to

yield the pure product. (76%). lHNMR (300 MHZ, D20,
ppm) 8.52 (dd, 1:63, 2H), 8.17 (dt, 1:78, 1:15, 2H), 7.72
(d, J:7.8, 2H), 7.64 (t, 1:63, 2H), 6.18-6.23 (m, 2H), 5.33
5.41 (m, 2H), 4.37 (t, J:7.1, 4H), 2.66 (s, 6H), 2.09 (q, 1:75,
4H), 1.72-1.82 (m, 4H), 1.36 (p, 1:75, 4H). l3CNMR,
155.26, 145.01, 144.73, 132.25, 130.23, 125.64, 124.15,
58.06, 29.10, 26.38, 25.61, 19.73.

/

Br

Br

+

/

E9
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/

N

/

Example 3

No

25

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7

diene-1,12-diyl)-bis-(3-methyl-pyridinium)dibro

cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a

mide

solution of 4-picoline (3 mmol) in acetonitrile and the solu
30

/

Br

Br

+

tion re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively
With ether until no picoline left in the aqueous layer The

resulting aqueous solution of the product Was lyophiliZed to

/

35

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.45 (d, 1:69, 4H), 7.68 (d, 1:69, 4H), 6.14-6.19 (m,
2H), 5.31-5.39 (m, 2H), 4.35 (t, J:7.2, 4H), 2.47 (s, 6H), 2.07
(q, J:7.2, 4H), 1.83 (p, 1:75, 4H), 1.25 (p, 1:75, 4H).
Example 5

40

T9

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7

diene-1,12-diyl)-bis-(5,6,7,8-tetrahydro-quino
linium)dibromide

/

N

45

/

Br
+

Br

/

/ ®\N

/

/

N @—

2B1 9

/

|

\
/
N

cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a

solution of 3-picoline (3 mmol) in acetonitrile and the solu
tion re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively

/

60

With ether until no picoline left in the aqueous layer. The
resulting aqueous solution of the product Was lyophiliZed to

yield the pure product. (76%). lHNMR (300 MHZ, D20,
ppm) 8.50 (s, 2H), 8.44 (d, 1:63, 2H), 8.16 (d, J:7.8, 2H),
7.74 (dd, 1:78, 1:63, 2H), 6.15-6.18 (m, 2H), 5.38-5.38 (m,
2H), 4.38 (t, 1:57, 4H), 2.35 (s, 6H), 2.06 (q, 1:75, 4H), 1.83

65

N (D

\5 /E
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/
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a

solution of 5,6,7,8-tetrahydro-quinoline (3 mmol) in acetoni
trile and the solution re?uxed for 24 hours. The acetonitrile
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Was removed in vacuum and the resulting residue Was parti
tioned between ether and Water. The aqueous layer Was

-continued

b

Washed extensively With ether until no quinoline left in the

aqueous layer. The resulting aqueous solution of the product
Was lyophiliZed to yield the pure product. (75%). lHNMR

5

(300 MHZ, D20, ppm), 8.35 (d, 1:63, 2H), 7.97 (d, 1:81,
2H), 7.52 (dd, 1:81, 1:63, 2H), 6.16-6.22 (m, 2H), 5.32
5.42 (m, 2H), 4.30 (t, J:7.8, 4H), 2.92 (t, 1:62, 4H), 2.79 (t,
1:62, 4H), 2.09 (q, J:7.2, 4H), 1.60-1.83 (m, 12H), 1.36 (p,

/

N

1:75, 4H).
Example 6
cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a

solution of 2,4-lutidine (3 mmol) in acetonitrile and the solu

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7

tion re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively
With ether until no 2,4-lutidine left in the aqueous layer. The

diene-1,12-diyl)-bis-(5,6,7,8-tetrahydro-isoquino
linium)dibromide
20

/

Br

/
25

\

resulting aqueous solution of the product Was lyophiliZed to

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.31 (d, 1:63, 2H), 7.53 (s, 2H), 7.46 (d, 1:69, 2H),
6.16-6.22 (m, 2H), 5.32-5.40 (m, 2H), 4.28 (t, 1:81, 4H),
2.58 (s, 3H), 2.38 (s, 3H), 2.07 (q, J:7.2, 4H), 1.74 (p, 1:75,
4H), 1.33 (p, 1:75, 4H). CNMR, 159.20, 153.87, 143.69,
132.32, 130.44, 126.34, 124.18, 57.19, 29.10, 26.41, 25.63,
21.19,19.46.

—>

Example 8

| N/

C(QNW Cb
/

N6

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7
diene-1, 12-diyl)-bis-(3,4-dimethyl-pyridinium)dibro
mide

35

cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a

solution of 5,6,7,8-tetrahydro-isoquinoline (3 mmol) in
acetonitrile and the solution re?uxed for 24 hours. The aceto
nitrile Was removed in vacuum and the resulting residue Was

/

(300 MHZ, D20, ppm), 8.30 (s, 2H), 8.19 (d, 1:66, 2H), 7.50
(d, 1:63, 2H), 6.09-6.16 (m, 2H), 5.28-5.36 (m, 2H), 4.27 (t,
J:7.2, 4H), 2.29-2.82 (hr, 4H), 2.67-2.74 (br, 4H), 2.02 (q,
J:7.2, 4H), 1.81 (p, 1:72, 4H), 1.62-1.69 (m, 8H), 1.22 (p,
1:72, 4H). CNMR158.82, 143.10, 139.60, 138.96, 132.28,
127.92, 124.09, 60.82, 49.13, 30.07, 29.35, 26.32, 26.20,

+

Br

partitioned betWeen ether and Water. The aqueous layer Was
Washed extensively With ether until no isoquinoline left in the

aqueous layer. The resulting aqueous solution of the product
Was lyophiliZed to yield the pure product. (75%). lHNMR

/
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Ti
/

N

50

/

25.43, 21.01.

/® \N
Example 7
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cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7

solution of 3,4-lutidine (3 mmol) in acetonitrile and the solu

diene- 1 ,12-diyl)-bis-(2,4-dimethyl-pyridinium)dibro
mide
60

tion re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively
With ether until no 3,4-lutidine left in the aqueous layer. The

resulting aqueous solution of the product Was lyophiliZed to
Br
Br

65

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.34 (s, 1H), 8.29 (d, 1:63, 1H), 7.60 (d, 1:63, 1H),
6.13-6.18 (m, 2H), 5.30-5.38 (m, 2H), 4.31 (t, 1:72, 4H),
2.37 (s, 3H), 2.25 (s, 3H), 2.05 (q, J:7.2, 4H), 1.81 (p, 1:75,

US 8,178,678 B2
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4H), 1.24 (p, 1:75, 4H). CNMR, 158.66, 142.37, 140.71,
138.65, 132.25, 128.23, 124.07, 60.80, 30.11, 26.31, 25.42,

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

of S-nicotine (3 mmol) in acetonitrile and the solution
re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen

19.69, 16.34.

Example 9

ether and Water. The aqueous layer Was Washed extensively
With ether until no S-nicotine left in the aqueous layer. The

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7

resulting aqueous solution of the product Was lyophiliZed to

diene- 1 ,12-diyl)-bis-(3,5-dimethyl-pyridinium)dibro

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.57-8.59 (m, 4H), 8.35 (d, 1:81, 2H), 7.88 (dd, 1:78,
1:66, 2H), 7.01 (s, 4H), 4.45 (t, 1:75, 4H), 3.40 (t, 2H),
3.04-3.10 (m, 2H), 2.49 (t, 1:75, 4H), 2.30-2.40 (m, 2H),
2.18-2.29 (m, 2H), 2.03 (s, 6H), 1.80-1.90 (m, 8H), 1.40-1.55
(m, 4H). CNMR, 144.65, 143.48, 143.30, 139.76, 128.74,
128.42, 67.61, 61.99, 56.62, 39.37, 33.96, 33.73, 30.17,

mide

Br
Br

27.28, 22.33.

Example 11
20

Synthesis of Compound N,N'-[1,4-phenylenedi-(4
butanyl)] -bis -(2 -methylpyri dinium)dibromide

BIWQMBI —>

cis-cis-1,12-Dibromo-dodeca-5,7-diene Was added to a

solution of 3,5-lutidine (3 mmol) in acetonitrile and the solu

30

tion re?uxed for 24 hours. The acetonitrile Was removed in

\

vacuum and the resulting residue Was partitioned between
ether and Water. The aqueous layer.Was Washed extensively
With ether until no 3,5-lutidine left in the aqueous layer. The
resulting aqueous solution of the product Was lyophiliZed to

/

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.29 (s, 4H), 7.99 (s, 2H), 6.12-6.18 (m, 2H), 5.30-5.38
(m, 2H), 4.31 (t, 1:75, 4H), 2.30 (s, 6H), 2.05 (q, J:7.2, 4H),
1.81 (p, 1:75, 4H), 1.24 (p, 1:75, 4H). CNMR, 146.56,
140.96, 139.11, 132.28, 124.09, 61.49, 30.21, 26.34, 25.43,

ZBre

/

35

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

of 2-picoline (3 mmol) in acetonitrile and the solution
40

17.73.

Example 10

re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively
With ether until no 2-picoline left in the aqueous layer. The

resulting aqueous solution of the product Was lyophiliZed to

Synthesis of Compound N,N'-[1,4-phenylenedi-(4
butanyl)] -bis- [3 -(2'-S-1-methyl-pyrrolidin-2-yl)
pyridinium] dibromide

BIWQNBI —>

H3C

21319

45

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.49 (dd, 1:60, 1.2, 2H), 8.17 (dt, 1:81, 1:15, 2H),
7.70 (d, 1:81, 2H), 7.65 (dt, 1:81, 1:12, 2H), 7.04 (s, 4H),
4.37 (t, 1:72, 4H), 2.62 (s, 6H), 2.51 (t, 1:72, 4H), 1.77 (p,

US 8,178,678 B2
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127.8, 4H), 1.57 (p, 127.8, 4H). CNMR. 145.05, 144.73,
139.79, 130.24, 128.78, 125.64, 58.02, 34.11, 29.01, 27.49,

1:75, 4H), 1.45 (p, 1:75, 4H). CNMR. 159.99, 143.04,
139.79, 128.74, 128.65, 60.99, 34.02, 30.03, 27.26, 21.50.

19.70.

Example 14
Example 12

Synthesis of Compound N,N'-[1,4-phenylenedi-(4

butanyl)]-bis-(3-ethylpyridinium)dibromide

Synthesis of Compound N,N'-[1,4-phenylenedi-(4

butanyl)]-bis-(3 -methylpyridinium)dibromide

Br/WQM Br _>

BI/WQNBI —>

@WQNW
/

ZBre

\

| /@ NW1.»
/

/

2Br e
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1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

of 3-picoline (3 mmol) in acetonitrile and the solution

of 3-ethylpyridine (3 mmol) in acetonitrile and the solution

re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively
With ether until no 3-picoline left in the aqueous layer. The

re?uxed for 24 hours. The acetonitrile Was removed in
5 vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively

With ether until no 3-ethylpyridine left in the aqueous layer.
The resulting aqueous solution of the product Was lyophiliZed

resulting aqueous solution of the product Was lyophiliZed to

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.45 (s, 2H), 8.40 (d, 126.6, 2H), 8.16 (d, 128.1, 2H),
7.72 (dd, 128.1, 126.0, 2H), 7.00 (s, 4H), 4.37 (t, 127.5, 4H),
2.47 (t, 127.5, 4H), 2.34 (s, 6H), 1.82 (p, 127.5, 4H), 1.46 (p,
127.5, 4H). CNMR. 146.02,143.68, 141.68,139.96, 139.79,
128.75, 127.46, 61.69, 34.04, 30.14, 27.28, 17.90.

to yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.45 (s, 2H), 8.41 (d, 1-6.0, 2H), 8.19 (d, 128.4, 2H),

35

7.73 (dd, 128.1, 126.0, 2H), 6.97 (s, 4H), 4.37 (t, 127.2, 4H),
2.66 (q, 7.8, 2H), 2.49 (t, 127.2, 1.83 (p, 127.5, 4H), 1.45 (p,
1-1.5, 4H), 1.09 (t, 127.8, 6H). CNMR. 145.61, 145.08,
143.09, 141.51, 139.78, 128.75, 127.68, 61.70, 34.01, 30.13,
27.24, 25.70, 13.92.

Example 13
Example 15

Synthesis of Compound N,N'-[1,4-phenylenedi-(4

40

Synthesis of Compound N,N'-[1,4-phenylenedi-(4
butanyl)] -bis-(5, 6,7, 8-tetrahydroquinolinium)dibro

butanyl)]-bis-(4-methylpyridinium)dibromide

mide
45
4

50
\

/

/

(E/

2Br e

2Bre

/

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution
1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

of 4-picoline (3 mmol) in acetonitrile and the solution
re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen

60

of tetrahydroquinoline (3 mmol) in acetonitrile and the solu

ether and Water. The aqueous layer Was Washed extensively
With ether until no 4-picoline left in the aqueous layer. The
resulting aqueous solution of the product Was lyophiliZed to

tion re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively
With ether until no tetrahydroquinoline left in the aqueous

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.38 (d, 126.9, 4H), 7.64 (d, 126.9, 4H), 6.98 (s, 4H),
4.33 (t, 127.2, 4H), 2.46 (t, 127.2, 4H), 2.44 (s, 6H), 1.81 (p,

philiZed to yieldthe pure product. (75%). lHNMR (300 MHZ,
D20, ppm), 8.30 (d, 126.3, 2H), 7.95 (d, 127.8, 2H), 7.49 (dd,

layer. The resulting aqueous solution of the product Was lyo

US 8,178,678 B2
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1:81, 1:63, 2H), 7.02 (s, 4H), 4.28 (I, 7.5, 4H), 2.83 (I,
1:75, 4H), 2.77 (I, 1:75, 4H), 2.49 (I, 1:75, 4H), 1.66-1.80
(m, 8H), 1.35-1.63 (m, 8H).

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

of (3-hydroxy-propyl)-pyridine (3 mmol) in acetonitrile and
the solution re?uxed for 24 hours. The acetonitrile Was
removed in vacuum and the resulting residue Was partitioned
betWeen ether and Water. The aqueous layer Was Washed

Example 16

extensively With ether until no (3 -hydroxy-propyl)-pyridine
left in the aqueous layer. The resulting aqueous solution of the

Synthesis of Compound N,N'-[1,4-phenylenedi-(4
butanyl)] -bis-(5, 6,7, 8-tetrahydroisoquinolinium)

product Was lyophiliZed to yield the pure product. (75%).

dibromide

lHNMR (300 MHZ, D20, ppm), 8.49 (s, 2H), 8.43 (d, 1:60,
2H), 8.22 (d, 1:81, 2H), 7.75 (dd, 1:78, 1:60, 2H), 6.98 (s,
4H), 4.38 (t, J:7.2, 4H), 3.45 (t, 1:66, 4H), 2.72 (t, 1:78,
4H), 2.46 (t, 1:75, 4H), 1.83 (p, 1:75, 4H), 1.70-1.75 )m,
4H), 1.44 (p, 1:75, 4H). CNMR, 145.53, 143.51, 141.78,
139.78, 128.75, 127.78, 61.75, 60.67, 34.01, 32.17, 30.13,

BI/WQNBI —>

28.81, 27.24.

Example 18

Synthesis of Compound N,N'-[1,4-phenylenedi-(4

butanyl)]-bis-(2,4-dimethylpyridinium)dibromide
\

/

/

ZBre

BIWQM Br _)

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

of tetrahydroisoquinoline (3 mmol) in acetonitrile and the

30

solution re?uxed for 24 hours. The acetonitrile Was removed

in vacuum and the resulting residue Was partitioned between
ether and Water. The aqueous layer Was Washed extensively
With ether until no tetrahydroisoquinoline left in the aqueous

layer. The resulting aqueous solution of the product Was lyo

philiZed to yieldthe pure product. (75%). lHNMR (300 MHZ,
D20, ppm), 8.21 (s, 2H), 8.13 (d, 1:63, 2H), 7.46 (d, 1:63,
2H), 6.96 (s, 4H), 4.25 (t, 1:72, 4H), 2.2.78-2.84 (hr, 4H),
2.63-2.70 (hr, 4H), 2.44 (t, 1:72, 4H), 1.78 (p, 1:75, 4H),
1.64-1.70 (m, 8H), 1.42 (p, 1:75, 4H). CNMR, 158.77,
143.03, 139.78, 139.56, 138.88, 128.72, 127.84, 60.79,
49.11, 34.01, 29.91, 29.31, 27.16, 26.16, 20.99.

35

/

40

45

butanyl)]-bis-[3-(3 -hydroxy-propyl)-pyridinium]
dibromide

ZBre

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively
With ether until no 2,4-lutidine left in the aqueous layer. The

resulting aqueous solution of the product Was lyophiliZed to

yield the pure product. (75%). lHNMR (300 MHZ, D20,
ppm), 8.27 (d, 1:66, 2H), 7.50 (s, 2H), 7.45 (d, 1:66, 2H),

BIWQMBI —>

HO

/

ZBIG

/

of 2,4-lutidine (3 mmol) in acetonitrile and the solution

Example 17

Synthesis of Compound N,N'-[1,4-phenylenedi-(4

\

/

OH

US 8,178,678 B2
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7.02 (s, 4H), 4.28 (t, 1:72, 4H), 2.52 (s, 6H), 2.48 (t, 1:72,
4H), 2.38 (s, 6H), 2.20 (s, 3H), 1.79 (p, 1:75, 4H), 1.42 (p,

1.45 (p, 1:75, CNMR, 146.50, 140.89, 139.79, 139.04,
128.74, 61.46, 34.04, 30.03, 27.22, 17.70.

1:75, 4H).

Example 21
Example 19

Synthesis of Compound 5 -[2-(5 -hydroxy-pent-1

ynyl)-phenyl]-pent-4-yn-1-ol
Synthesis of Compound N,N'-[1,4-phenylenedi-(4

butanyl)]-bis-(3,4-dimethylpyridinium)dibromide

%

BIWQNBI _>
/

2Bre

%

OH

OH

1,2-DibromobenZene (10.94 g, 46.37 mmol), 4-pentyn-1
01 (9.36 g, 111.30 mmol), and bis(triphenylphosphine)palla

/

dium(ll) dichloride (650 mg, 0.93 mmol) Was stirred in tri

ethylamine (150 mL) under nitrogen for 5 min. Copper(l)
iodide (88 mg, 0.46 mmol) Was added and the mixture Was
stirred for 4 hrs at 85° C. for 6 days. The mixture Was cooled
to room temperature and ?ltered through a celite pad, rinsed
With ethylacetate. The combined ?ltrate Was evaporated to
dryness under reduced pressure. The resulting residue Was

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

of 3,4-lutidine (3 mmol) in acetonitrile and the solution
re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen
ether and Water. The aqueous layer Was Washed extensively
With ether until no 3,4-lutidine left in the aqueous layer. The

resulting aqueous solution of the product Was lyophiliZed to

puri?ed by column chromatography (chloroformzmethanol
30: 1) to afford 5.33 g of the title compound. Yield: 47%. 1H
30

yield the pure product. (75%). lHNMR (300 MHZ, DZO,
ppm), 8.25 (s, 2H), 8.22 (d, 1:60, 2H), 7.55 (d, 1:60, 2H),
6.96 (s, 4H), 4.27 (t, 1:72, 4H), 2.45 (t, J:7.2, 4H), 2.34 (s,
6H), 2.21 (s, 6H), 1.79 (p, 1:75, 4H), 1.42 (p, 1:75, 4H).
CNMR, 158.64, 142.28, 140.66, 139.78, 138.61, 128.72,

NMR (300 MHZ, D20) 6 1.85 (m, 4H), 2.58 (t, 1:66 HZ, 4H),
3.82 (t, 1:60 HZ, 4H), 7.18 (m, 2H), 7.36 (m, 2H) ppm; 13C
NMR (75 MHZ, CDCl3) 6 16.3, 31.4, 62.4, 80.2, 93.3, 126.0,
127.4, 131.8 ppm.

Example 22

128.18, 34.02, 29.94, 27.20, 19.67, 16.29.

Synthesis of Compound

1,2-bis-(5-bromo-pent-1-ynyl)-benZene

Example 20
40

Synthesis of Compound N,N'-[1,4-phenylenedi-(4

butanyl)]-bis-(3,5-dimethylpyridinium)dibromide

%

OH

%

OH

45

50

%

Br

%

Br

55

5 -[2-(5-Hydroxy-pent-1-ynyl)-phenyl]-pent-4-yn-1-ol

1,4-Bis-(4-bromo-butyl)-benZene Was added to a solution

(2.40 g, 9.90 mmol) and carbon tetrabromide (8.21 g, 24.75
mmol) Were dissolved in dry methylene chloride (30 mL) and
cooled to 00 C. Triphenyl phosphine (6.82 g, 25.99 mmol) in
methylene chloride (15 mL) Was added dropWise and the

of 3,5-lutidine (3 mmol) in acetonitrile and the solution
re?uxed for 24 hours. The acetonitrile Was removed in
vacuum and the resulting residue Was partitioned betWeen

ether and Water. The aqueous layer Was Washed extensively
With ether until no 3,5-lutidine left in the aqueous layer. The
resulting aqueous solution of the product Was lyophiliZed to

yield the pure product. (75%). lHNMR (300 MHZ, DZO,
ppm), 8.23 (s, 4H), 7.97 (s, 2H), 6.97 (s, 4H), 4.29 (t, 1:72,
4H), 2.45 (t, J:7.2, 4H), 2.27 (s, 12H), 1.81 (p, 1:75, 4H),

mixture Was stirred for 1 h at 0° C. The mixture Was poured

65

into hexanes (200 mL) and then ?ltered through a short silica
gel column, Washed With ethylacetate/hexanes (1/4). The com
bined organic solvents Were evaporated to dryness under
reduced pressure. The resulting residue Was puri?ed by col
umn chromatography (hexaneszethylacetate 30:1) to afford

US 8,178,678 B2
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2.48 g of the title compound. Yield: 68%. 1H NMR (300 MHZ,

-Continued

CDCl3) 6 2.16 (m, 4H), 2.68 (t, 1:66 HZ, 4H), 3.65 (dt, 1:66,
0.6 HZ, 4H), 7.20 (m, 2H), 7.38 (m, 2H) ppm; 13C NMR (75

MHZ, CDCl3) 6 18.6, 31.8, 32.7, 80.7, 91.8, 125.9, 127.6,

131.9 ppm.
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Example 23

_

%
Synthesis of Compound 1,2-bis-[5-(2-methyl-pyri-

N®

10

\

/

dinium) -p ent-1 -ynyl] -b enZene dibromide

A mixture of 1 ,2-bis-(5 -bromo-pent-1-ynyl)-benZene (270
%

Br

%

Br

15 mg, 0.73 mmol) and 3-picoline (1 mL) Was heated at 60-70o
C. for 12 hrs. The resulted mixture Was Washed With diethyl
ether and then dissolved in Water (15 mL), the aqueous solu
tion Was extracted With diethyl ether (30 mL><3). Water Was
20 removed by lyophiliZation to afford 350 mg of the title com

pound. Yield: 86%. 1H NMR (300 MHZ, CD3OD) 6 2.45 (m,
4H), 2.56 (s, 6H) 2.78 (1, F66 HZ, 4H), 4.95 (r, J :72 HZ,
4H), 7.22-7.42 (m, 4H), 8.05 (dd, 1:81, 6.0 HZ, 2H), 8.39 (d,
1:78 HZ, 2H), 9.10 (d, 1:60 HZ, 2H), 9.19 (s, 2H) ppm; 13c
,5 NMR (75 MHZ, @3013) 6 17.6, 18.9, 31.2, 61.9, 81.6, 92.8,
126.4, 128.7, 129.0, 132.9, 140.9,143.1,145.6,147.3 ppm.
N@

/

\

Exam le 25

/

p
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%

Synthesis of Compound 1,2-bis-[5-(4-methyl-pyri
dinium)-pent-l -ynyl]-benZene dibromide

NE)
35

/
/

Br

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (264

—>

mg, 0.72 mmol) and 2-picoline (1 mL) Was heated at 60-700
C. for 12 hrs. The resulted mixture Was Washed With diethyl 40
ether and then dissolved in Water (15 mL), the aqueous solution Was extracted With diethyl ether (30 mL><3). Water Was
removed by lyophiliZation to afford 327 mg of the title com

\
\

Br

pound.Yield: 82 %. 1H NMR (300 MHZ, CD3OD) 6 2.35 (m, 45
4H), 2.81 (t, J :66 HZ, 4H), 3.02 (s, 6H), 4.91 (t, J :75 HZ,

4H), 7.27-7.50 (m, 4H), 7.92-8.15 (m, 4H), 8.45 (t, J:7.8 HZ,
2H), 9.11 (d, 1:63 HZ, 2H) m; 13C NMR (75 MHZ, CD3OD)
6 17.6, 21.1, 30.1, 5.8.2, 81.9, 92.9, 126.4, 127.0, 129.2,
129.3,131.5,133.1,146.4,156.7 ppm.

_
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Example 24
Synthesis of Compound 1,2-bis-[5-(3-methyl-pyri-

dinium) -pent-1 -ynyl] -benZene dibromide

55

%

N ('3

\

/

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (268
%

60 mg, 0.73 mmol) and 4-picoline (1 mL) Was heated at 60-70o
C. for 12 hrs. The resulted mixture Was Washed With diethyl
ether and then dissolved in Water (15 mL), the aqueous solu

Br
—’

%

Br

tion Was extracted With diethyl ether (30 mL><3). Water Was
removed by lyophiliZation to afford 435 mg of the title com

65 pound. Yield: 86%. 1H NMR (300 MHZ, CD3OD) 6 2.41 (m,
4H), 2.51 (s, 6H), 2.78 (1, F66 HZ, 4H 4.91 (1, F66 HZ, 4H),
7.30 (s, 4H), 7.92 (d, 1:63 HZ, 4H), 9.05 (d, 1:63 HZ, 4H)

US 8,178,678 B2
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ppm; 13C NMR (75 MHZ, CD3OD) 6 17.5, 22.3, 31.0, 61.4,
81.5, 92.8, 126.4, 129.0, 129.8, 132.9, 144.9, 161.1 ppm.

-continued

Example 26

%

N®

%

N@

Synthesis of Compound 1,2-bis-[5-(2,4-dimethyl
pyridinium) -p ent-1 -ynyl] -b enZene dibromide

Br

%

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (276
mg, 0.75 mmol) and 3,4-lutidine (1 mL) Was heated at 60-700

//

Br

20

25

C. for 12 hrs. The resulted mixture Was Washed With diethyl
ether and then dissolved in Water (15 mL), the aqueous solu
tion Was extracted With diethyl ether (30 mL><3). Water Was
removed by lyophiliZation to afford 355 mg of the title com

pound. Yield: 81%. 1H NMR (300 MHZ, CD3OD) 6 2.37 (s,
3H), 2.40 (s, 3H), 2.44 (m, 4H), 2.79 (t, 1:66 HZ, 4H), 4.88
(t, 1:66 HZ, 4H), 7.29 (s, 4H), 7.86 (d, 1:63 HZ, 2H), 8.95 (d,
1:63 HZ, 2H), 9.06 (s, 2H), ppm; 13C NMR (75 MHZ,
CD3OD) 6 17.3, 17.7, 20.4, 31.1, 61.2, 81.3, 93.0, 126.5,
129.0, 129.4, 132.8, 139.5, 142.7,144.3,159.8 ppm.

@
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Example 28

2Bre
Synthesis of Compound 1,2-bis-[5-(3,5-dimethyl

%

pyridinium) -p ent-1 -ynyl] -b enZene dibromide

N9

\ /
Br

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (268
mg, 0.73 mmol) and 2,4-lutidine (1 mL) Was heated at 60-700
C. for 12 hrs. The resulted mixture Was Washed With diethyl
ether and then dissolved in Water (15 mL), the aqueous solu
tion Was extracted With diethyl ether (30 mL><3). Water Was
removed by lyophiliZation to afford 343 mg of the title com

pound.Yield: 81%. 1H NMR (300 MHZ, CD3OD) 6 2.34 (m,
4H), 2.52 (s, 3H), 2.84 (t, 1:66 HZ, 4H), 2.97 (s, 3H), 4.87 (t,
J:7.5 HZ, 4H), 7.27-7.45 (m, 4H), 7.80 (d, 1:63 HZ, 2H),
7.87 (s, 2H), 8.99 (d, 1:63 HZ, 2H) ppm; l3CNMR (75 MHZ,
CD3OD) 6 17.6, 20.9, 22.0, 30.1, 57.5, 81.6, 93.0, 126.4,
127.6,129.1,131.7,133.0,145.5,155.5,160.3 ppm.

40

\\
//
Br

45
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Example 27

Synthesis of Compound 1,2-bis-[5-(3,4-dimethyl
pyridinium) -p ent-1 -ynyl] -b enZene dibromide

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (280
60

C. for 12 hrs. The resulted mixture Was Washed With diethyl
ether and then dissolved in Water (15 mL), the aqueous solu
tion Was extracted With diethyl ether (30 mL><3). Water Was
removed by lyophiliZation to afford 363 mg of the title com

Br

//

Br

mg, 0.76 mmol) and 3,5-lutidine (1 mL) Was heated at 60-700

65

pound. Yield: 82%. 1H NMR (300 MHZ, CD3OD) 6 2.42 (m,
4H), 2.51 (s, 6H), 2.76 (t, 1:69 HZ, 4H), 4.86 (t, 1:69 HZ,
4H), 7.30 (m, 4H), 8.13 (s, 2H), 8.95 (s,4H) ppm; 13C NMR

US 8,178,678 B2
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(75 MHZ, CD3OD) 6 17.7, 18.7, 31.2, 61.9, 81.6, 92.9, 126.6,

-continued

129.0, 132.8, 140.2, 142.9, 147.9 ppm.

Example 29

%

01

Synthesis of Compound
1 ,2-bis-(5 -quinolinium-pent-1-ynyl)-benZene

%

dibromide

%

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (252

Br

%

mg, 0.68 mmol) and isoquinoline (1 mL) Was heated at 60-700
C. for 12 hrs. The resulted mixture Was Washed With diethyl
ether and then dissolved in Water (30 mL), the aqueous solu
tion Was extracted With chloroform (20 mL><3). Water Was
removed by lyophiliZation to afford 319 mg of the title com

Br
20

%

N? /

25

pound. Yield: 74%. 1H NMR (300 MHZ, CD3OD) 6 2.46 (m,
4H), 2.77 (t, 1:63 HZ, 4H), 5.01 (t, 1:66 HZ, 4H), 6.91 (m,
2H), 7.04 (m, 2H), 7.90-8.50 (m, 10H), 8.78 (d, 1:69 HZ,
2H), 10.10 (s, 2H) ppm; l3CNMR (75 MHZ, CD3OD) 6 17.8,
30.8, 62.1, 81.3, 92.7, 125.7, 127.3, 128.1, 128.5, 131.2,
131.4,132.1,132.2,135.6,137.9,138.4,150.8 ppm.

2Bre
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Example 31

Synthesis of Compound 1,2-bis-[5-(2'-S-nicotinium
30

35

pent- 1 -ynyl)]benZene dibromide

%

Br

%

Br

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (249
mg, 0.68 mmol) and quinoline (1 mL) Was heated at 60-700 C.
for 12 hrs. The resulted mixture Was Washed With diethyl
ether and then dissolved in Water (30 mL), the aqueous solu
tion Was extracted With chloroform (20 mL><3). Water Was
removed by lyophiliZation to afford 317 mg of the title com

40

pound.Yield: 75 %. 1H NMR (300 MHZ, CD3OD) 6 2.42 (m,
4H), 2.78 (t, 1:66 HZ, 4H), 5.36 (t, 1:69 HZ, 4H), 7.02-7.28
(m, 4H), 7.97 (t, J :7.5 HZ, 2H), 8.07-8.40 (m, 4H), 8.67 (d,
J:9.0 HZ, 2H), 9.15 (d, J:8.4 HZ, 2H), 9.15 (d, J:8.4 HZ, 2H),
9.70 (d, J:5.7 HZ, 2H) ppm; 13C NMR (75 MHZ, CD3OD) 6

45

,0.

\

_

%

CH3

N? /

178,298, 58.5, 81.6, 92.9, 119.7, 123.2, 126.2, 129.0, 130.5,
131.3, 132.0, 132.7, 137.2, 139.0, 149.0, 150.6 ppm.

21319
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Example 30

%

NJ
\ /

CH3
/
N

Synthesis of Compound

1,2-bis-(5 -isoquinolinium-pent-1-ynyl)-benZene

55

dibromide

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benZene (330
60

%

Br

%

Br

mg, 0.90 mmol) and S-nicotine (1 mL) Was heated at 60-700
C. for 12 hrs. The resulted mixture Was Washed With diethyl
ether and then dissolved in Water (20 mL), the aqueous solu
tion Was extracted With chloroform (20 mL><3). Water Was
removed by lyophiliZation to afford 340 mg of the title com

pound.Yield: 55%. 1H NMR (300 MHZ, CD3OD) 6 2.00-2.82
65

(m, 16H), 2.55 (s, 6H), 2.90 (m, 2H), 3.55 (m, 2H), 4.17 (m,
2H), 4.95 (t, 1:69 HZ, 4H), 7.27 (m, 2H), 7.37 (m, 2H), 8.17
(dd, J:7.8, 6.3 HZ, 2H), 8.69 (d, J:8.4 HZ, 2H), 9.15 (d, 1:60

